Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PERA-8103
- Development stage
- Preclinical
- Lead developer
- Merck KGaA
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PERA-8103 is a preclinical small molecule agonist of the luteinizing hormone/choriogonadotropin receptor (LHCGR) originally developed by PostEra using its artificial intelligence platform, Proton. It is designed as an oral alternative to injectable human chorionic gonadotropin (hCG) regimens for the treatment of male infertility and as an ovulation trigger in in vitro fertilization (IVF). In September 2026, EMD Serono, the healthcare business of Merck KGaA, acquired the program outright, assuming sole responsibility for its continued global development and potential commercialization.
- Other names
- PERA 8103PERA8103PERA-8103
02
Targets
LHCGR (Luteinizing hormone/choriogonadotropin receptor)
Beyond the preview
Go deeper on PERA-8103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PERA-8103.